Majed M. Abuhajir, MD
Institution
Christus Health
Physician Status
accepting new patients
patient
Jayastu Senapati, MBBS, MD, DM
Institution
The University of Texas MD Anderson Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Anurag Singh, MD
Institution
The University of Kansas
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Dr. Singh completed his Internal Medicine Residency as well as his Hematology and Oncology Fellowship at the State University of New York Upstate Medical University. His clinical interests include mismatched donor stem cell transplantation , Hereditary predisposition to hematologic malignancies and Cellular therapies. His research interests include donor selection in stem cell transplantation, Transplantation for myeloid malignancies , GVHD prophylaxis and germline predisposition to Hematological malignancies
AAMDSIF Calls for Restoration of Bone Marrow Failure Research Funding
Original Publication Date
Article Source
Coalition Action
The Aplastic Anemia and MDS International Foundation joined 156 other members of the Defense Health Research Consortium (DHRC) in calling for Congress to restore funding in Fiscal Year 2025 for the Congressionally Directed Medical Research Program (CDMRP) which includes the Bone…
High Risk MDS - 2025 Kansas City Patient and Family Conference
Topic(s)
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML)
In this recording, Dr. Jesus Gonazlez Lugo discusses the diagnosis of High Risk MDS and the evolution to AML along with treatment options for patients. Recording includes the question-and-answer session.
Aplastic Anemia - 2025 Kansas City Patient and Family Conference
Topic(s)
Aplastic Anemia
Presenter(s)
Taha Bat, MD
In this recording, Dr. Taha Bat discusses the diagnosis of aplastic anemia along with treatment options for patients. Recording includes the question-and-answer session.
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients
Original Publication Date
Article Source
External Web Content
Abstract Hypomethylating agent (HMA) plus venetoclax (VEN) regimens are standard of care in patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy. While the VEN label recommends continuous 28-day cycles, shortened VEN durations may induce similar…
Cell-autonomous dysregulation of interferon signaling drives clonal expansion of SRSF2-mutant MDS stem/progenitor cells
Original Publication Date
Article Source
External Web Content
Key Points SRSF2 mutations blunt responsiveness of MDS cells to IFN stimulation and promote their clonal fitness by downregulating STAT1 expression Proteasome inhibition restores STAT1 protein level and sensitivity of SRSF2-mutant MDS cells to IFN, suggesting a new therapeutic…
Natural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes
Original Publication Date
Article Source
External Web Content
Abstract Dissecting the preneoplastic disease states’ biological mechanisms that precede tumorigenesis can lead to interventions that can slow down disease progression and/or mitigate disease-related comorbidities. Myelodysplastic syndromes (MDS) cannot be cured by currently…